Pre-AIDS mortality from natural causes associated with HIV disease progression: evidence from the European Seroconverter Study among injecting drug users

被引:58
作者
Prins, M
Aguado, IH
Brettle, RP
Robertson, JR
Broers, B
Carre, N
Goldberg, DJ
Zangerle, R
Coutinho, RA
vandenHoek, A
机构
[1] UNIV ALICANTE, VALENCIAN HIV SEROCONVERS STUDY, DEPT PUBL HLTH, E-03080 ALICANTE, SPAIN
[2] CITY HOSP EDINBURGH, INFECT DIS UNIT, EDINBURGH EH10 5SB, MIDLOTHIAN, SCOTLAND
[3] MUIRHOUSE MED GRP, EDINBURGH DRUG ADDICT STUDY, EDINBURGH, MIDLOTHIAN, SCOTLAND
[4] UNIV HOSP GENEVA, DIV INFECT DIS, GENEVA, SWITZERLAND
[5] HOP BICETRE, INSERM, U292, SEROCO STUDY GRP, LE KREMLIN BICETRE, FRANCE
[6] RUCHILL HOSP, SCOTTISH CTR INFECT & ENVIRONM HLTH, GLASGOW, LANARK, SCOTLAND
[7] UNIV INNSBRUCK, AIDS UNIT, A-6020 INNSBRUCK, AUSTRIA
关键词
injecting drug users; pre-AIDS mortality; HIV disease progression;
D O I
10.1097/00002030-199714000-00012
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To study differences in pre-AIDS mortality between European cohorts of injecting drug users (IDU) and to evaluate whether pre-AIDS mortality increased with time since HIV seroconversion and decreasing CD4 count. Methods: The study population consisted of 664 IDU with documented intervals of HIV seroconversion from eight cohort studies. Differences in pre-AIDS mortality were studied between European sites; an evaluation of whether pre-AIDS mortality increased with time since HIV seroconversion and decreasing CD4 count was carried out using Poisson regression. Results: One hundred and seven IDU died, of whom 57 did not have AIDS. Pre-AIDS causes of death were overdose/suicide (49%), natural causes-such as bacterial infections/cirrhosis (40%), and unintentional injuries/unknown (11%). Considering pre-AIDS death and AIDS as competing risks, 14.7% were expected to have died without AIDS and 17.3% to have developed AIDS at 7 years from seroconversion. No statistically significant differences in pre-AIDS mortality were found between European regions, men and women, age categories and calendar time periods. Overall pre-AIDS mortality did not increase with time since seroconversion, but did increase with decreasing CD4 count. Evaluating cause-specific mortality, only pre-AIDS mortality from natural causes appeared to be associated with time since seroconversion as well as immunosuppression. For natural causes, the death rate per 100 person-years was 0.13 the first 2 years after seroconversion, 0.73 in years 2-4 [risk relative (RR) to years 0-2, 5.6], 1.83 in years 4-6 (RR, 14.0) and 1.54 for greater than or equal to 6 years (RR, 11.7). This rate was 0 for a CD4 cell count greater than or equal to 500 x 10(6)/l, 1.06 for 200-500 x 10(6)/l and 4.06 for < 200 x 10(6)/l (RR versus greater than or equal to 200 x 10(6)/l, 7.0). In multivariate analysis, both CD4 count and time since seroconversion appeared to be independently associated with death from natural causes; CD4 count appeared to be the strongest predictor (adjusted RR, 5.9). Conclusions: A high pre-AIDS mortality rate was observed among IDU. No significant differences were observed across European sites. Pre-AIDS mortality from natural causes but not from overdose and suicide was associated with HIV disease progression.
引用
收藏
页码:1747 / 1756
页数:10
相关论文
共 36 条
[1]  
Andersen PK., 2012, Statistical models based on counting processes
[2]   HUMAN-IMMUNODEFICIENCY-VIRUS AND DRUG MISUSE - THE EDINBURGH EXPERIENCE [J].
BRETTLE, RP ;
BISSET, K ;
BURNS, S ;
DAVIDSON, J ;
DAVIDSON, SJ ;
GRAY, JMN ;
INGLIS, JM ;
LEES, JS ;
MOK, J .
BRITISH MEDICAL JOURNAL, 1987, 295 (6595) :421-424
[3]   EFFECT OF AGE AND EXPOSURE GROUP ON THE ONSET OF AIDS IN HETEROSEXUAL AND HOMOSEXUAL HIV-INFECTED PATIENTS [J].
CARRE, N ;
DEVEAU, C ;
BELANGER, F ;
BOUFASSA, F ;
PERSOZ, A ;
JADAND, C ;
ROUZIOUX, C ;
DELFRAISSY, JF ;
BUCQUET, D ;
DELLAMONICA, P ;
GALLAIS, H ;
DORMONT, J ;
LEFRERE, JJ ;
CASSUTO, JP ;
DUPONT, B ;
VITTECOQ, D ;
HERSON, S ;
GASTAUT, JA ;
SERENI, D ;
VILDE, JL ;
BRUCKER, G ;
KATLAMA, C ;
SOBEL, A ;
DUVAL, J ;
KAZATCHINE, M ;
LEBRAS, P ;
EVEN, P ;
GUILLEVIN, L .
AIDS, 1994, 8 (06) :797-802
[4]  
Centers for Disease Control (CDC), 1987, MMWR Suppl, V36, p1S
[5]  
Darby SC, 1996, LANCET, V347, P1573, DOI 10.1016/S0140-6736(96)91073-9
[6]  
DESJARLAIS DC, 1988, REV INFECT DIS, V10, P151
[7]   DIFFERENCES IN MORTALITY-RATES AND CAUSES OF DEATH BETWEEN HIV-POSITIVE AND HIV-NEGATIVE INTRAVENOUS-DRUG-USERS [J].
ESKILD, A ;
MAGNUS, P ;
SAMUELSEN, SO ;
SOHLBERG, C ;
KITTELSEN, P .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1993, 22 (02) :315-320
[8]  
Frischer M, 1997, ADDICTION, V92, P419, DOI 10.1046/j.1360-0443.1997.9244196.x
[9]   MORTALITY OF INTRAVENOUS-DRUG-USERS LIVING IN MILAN, ITALY - ROLE OF HIV-1 INFECTION [J].
GALLI, M ;
MUSICCO, M .
AIDS, 1994, 8 (10) :1457-1463
[10]   Mortality among drug users in the AIDS era [J].
Goedert, JJ ;
Pizza, G ;
Gritti, FM ;
Costigiola, P ;
Boschini, A ;
Bini, A ;
Lazzari, C ;
Palareti, A .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1995, 24 (06) :1204-1210